The short version of visceral fat fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-02 and is reviewed periodically as new material appears.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Romania derives from the local name for Romanian (Romanian: român), which in turn derives from Latin romanus, meaning "Roman" or "of Rome". This ethnonym for Romanians is first attested in the sixteenth century by Italian humanists travelling in Transylvania, Moldavia, and Wallachia. The oldest known surviving document written in Romanian that can be precisely dated, a 1521 letter known as the "Letter of Neacșu from Câmpulung", is notable for including the first documented occurrence of Romanian in a country name: Wallachia is mentioned as Țara Rumânească.
=== Dependent territories === Aruba Bermuda Curaçao Gibraltar Guernsey Isle of Man Jersey Sint Maarten Dependent territories of member states are not members in their own right, but may have membership as part of their sovereign state. As of January 2021, the Dutch Caribbean and the British territories of Guernsey, Jersey, the Isle of Man, Gibraltar, and Bermuda are included as part of the OECD memberships of the Netherlands and the UK, respectively. Other dependent territories of OECD member states are not members of the OECD.
=== From "geothermal" brine === A potential source of lithium is the leachates of geothermal wells, carried to the surface. Recovery of lithium has been demonstrated in the field; the lithium is separated by simple precipitation and filtration. The process and environmental costs are primarily those of the already-operating well; net environmental impacts may thus be positive. The brine of United Downs Deep Geothermal Power project near Redruth is claimed by Cornish Lithium to be valuable due to its high lithium concentration (220 mg/L) with low magnesium (<5 mg/L) and total dissolved solids content of <29g/L, and a flow rate of 40-60l/s.
== S == Paul Sabatier (1854–1941), French chemist, 1912 Nobel Prize in Chemistry corecipient Frederick Sanger (1918–2013), 1958 and 1980 Nobel Prize in Chemistry Carl Wilhelm Scheele (1742–1786), Swedish 18th century chemist, discovered numerous elements Christian Friedrich Schönbein (1799–1868), German-Swiss chemist, invented the fuel cell, and discovered gun cotton and ozone Stuart L. Schreiber (born 1956), American chemist, a pioneer in a field of chemical biology Richard R. Schrock (born 1945), 2005 Nobel Prize in Chemistry Peter Schultz (born 1956), American chemist Glenn T. Seaborg (1912–1999), 1951 Nobel Prize in Chemistry Nils Gabriel Sefström (1787–1845), chemist Francesco Selmi (1817–1881), Italian chemist, regarded as one of the founders of colloid chemistry Nikolay Nikolayevich Semyonov (1896–1986), physicist and chemist, 1956 Nobel Prize in Chemistry T. R. Seshadri (1900–1975), Indian chemist, pioneer in plant chemistry K. Barry Sharpless (born 1941), 2001 Wolf Prize in Chemistry, 2001 Nobel Prize in Chemistry Dan Shechtman (born 1941), 2011 Nobel Prize in Chemistry, discovered quasicrystals Patsy O.
Sources: en.wikipedia.org
Jindřich "Henry" Kopeček (born January 27, 1940) is a Czech-American chemist. He is a professor of pharmaceutical chemistry and a professor of biomedical engineering at the University of Utah in Salt Lake City, Utah. Kopeček is also an honorary professor at Sichuan University in Chengdu, China. His research focuses on biorecognition of macromolecules, bioconjugate chemistry, drug delivery systems, self-assembled biomaterials, and drug-free macromolecular therapeutics. Kopeček is regarded as one of the pioneers in development of biomedicinal polymers such as hydrogel implants and design of new polymer-drug conjugates. He was a key figure in a group which created the first clinically tested polymeric cancerostatics (PK1 and PK2). Hydrogels from his laboratory have been in clinical use. He was elected a member of the U.S. National Academy of Engineering in 2011 for contributions to the design of hydrogel biomaterials and polymeric drug delivery systems. In 2018, he was elected Fellow of the National Academy of Inventors. As of July 15, 2021, Kopeček has been cited over 35,000 times, with an h-index of 100, and I-10 index of 408.
== Development == All T cells derive from progenitor cells in the bone marrow, which become committed to their lineage in the thymus. All T cells begin as CD4-CD8-TCR- cells at the DN (double-negative) stage, where an individual cell will rearrange its T cell receptor genes to form a unique, functional molecule, which they, in turn, test against cells in the thymic cortex for a minimal level of interaction with self-MHC. If they receive these signals, they proliferate and express both CD4 and CD8, becoming double-positive cells. The selection of Tregs occurs on radio-resistant hematopoietically derived MHC class II-expressing cells in the medulla or Hassall's corpuscles in the thymus. At the DP (double-positive) stage, they are selected by their interaction with the cells within the thymus, begin the transcription of Foxp3, and become Treg cells, although they may not begin to express Foxp3 until the single-positive stage, at which point they are functional Tregs. Tregs do not have the limited TCR expression of NKT or γδ T cells; Tregs have a larger TCR diversity than effector T cells, biased towards self-peptides. The process of Treg selection is determined by the affinity of interaction with the self-peptide MHC complex. Selection to become a Treg is a "Goldilocks" process - i.e. not too high, not too low, but just right; a T cell that receives very strong signals will undergo apoptotic death; a cell that receives a weak signal will survive and be selected to become an effector cell. If a T cell receives an intermediate signal, then it will become a regulatory cell.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
Following the September 2 bombing in Davao City that killed 14 people in the city's central business district, on September 3 Duterte declared a "state of lawlessness", and on the following day issued Proclamation No. 55 to officially declare a "state of national emergency on account of lawless violence in Mindanao". On December 7, Duterte signed Executive Order No. 10 creating a consultative committee to review the 1987 Constitution of the Philippines. Duterte adjusted to working and residing at the Malacañang Palace by dividing his workweek between Manila and Davao City, spending three days in each city and utilizing the Malacañang of the South while in Davao. A Pulse Asia survey conducted from July 2–8 showed that Duterte had a trust rating of 91%, the highest of the six presidents since the Marcos dictatorship. In December 2016, Duterte was ranked 70th on Forbes list of The World's Most Powerful People.
Beta decay does not change the number (A) of nucleons in the nucleus, but changes only its charge Z. Thus the set of all nuclides with the same A can be introduced; these isobaric nuclides may turn into each other via beta decay. For a given A there is one that is most stable. It is said to be beta stable, because it presents a local minimum of the mass excess: if such a nucleus has (A, Z) numbers, the neighbour nuclei (A, Z−1) and (A, Z+1) have higher mass excess and can beta decay into (A, Z), but not vice versa. For all odd mass numbers A, there is only one known beta-stable isobar. For even A, there are up to three different beta-stable isobars experimentally known; for example, 12450Sn, 12452Te, and 12454Xe are all beta-stable. There are about 350 known beta-decay stable nuclides.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.